Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of neoadjuvant immune checkpoint inhibitors in patients with localized mismatch repair deficient colorectal cancer: A systematic review.
Authors
Udhayvir Singh Grewal
University of Iowa Hospitals and Clinics, Iowa City, IA;
Udhayvir Singh Grewal , Kruti Bhagirath Vora , Aparna Raj Parikh , Amit Mahipal , Sakti Chakrabarti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 149)
DOI
10.1200/JCO.2023.41.4_suppl.149
Abstract #
149
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study.
First Author: Alessandra Anna Anna Prete
Poster
2020 ASCO Virtual Scientific Program
The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy.
First Author: Hongyun Zhao
Poster
2016 ASCO Annual Meeting
Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR).
First Author: Daphne Day